Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27974155 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CYP1A2CYP2C9CYP2C19KEAP1 | |
| SCHEMBL6492647 | 0.86 | ALDH1A1 (0.52) | ALDH1A1CYP1A2CYP2C9CYP2C19KEAP1 | |
| Sulfuric Acid SCHEMBL10708662 | 0.83 | CYP1A2 (0.48) | ALDH1A1CYP1A2CYP2C9CYP2C19LMNA | |
| SCHEMBL30565328 | 0.81 | KEAP1 (0.49) | ALDH1A1CYP1A2CYP2C9CYP2C19KEAP1 | |
| SCHEMBL28349693 | 0.81 | ALDH1A1 (0.47) | ALDH1A1CYP1A2CYP2C9CYP2C19KEAP1 | |
| SCHEMBL28349697 | 0.81 | ALDH1A1 (0.47) | ALDH1A1CYP1A2CYP2C9CYP2C19KEAP1 | |
| SCHEMBL7425681 | 0.81 | ALDH1A1 (0.47) | ALDH1A1CYP1A2CYP2C9CYP2C19KEAP1 | |
| SCHEMBL333604 | 0.81 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2C9CYP2C19KEAP1 | |
| SCHEMBL875437 | 0.81 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2C9CYP2C19KEAP1 | |
| SCHEMBL11106443 | 0.80 | CYP1A2 (0.46) | ALDH1A1CYP1A2CYP2C9CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2578577-A1 | Sulfonyl esters of tetrahydrocannabinol and derivatives thereof | Albany Molecular Research, Inc. (US) | 2013-04-10 | — | — | EP | claimed |
| US-7674922-B2 | Process for production of delta-9-tetrahydrocannabinol | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-03-09 | — | — | US | claimed |
| EP-1928853-A2 | PROCESS FOR PRODUCTION OF DELTA-9-TETRAHYDROCANNABINOL | AMR Technology, Inc. (US) | 2008-06-11 | — | — | EP | claimed |
| US-20070093665-A1 | Process for production of delta-9- tetrahydrocannabinol | AMR TECHNOLOGY, INC. (US) | 2007-04-26 | — | — | US | claimed |
| WO-2007041167-A2 | PROCESS FOR PRODUCTION OF DELTA-9-TETRAHYDROCANNABINOL | AMR TECHNOLOGY, INC. (US) | 2007-04-12 | — | — | WO | claimed |
| CN-113164420-A | Therapeutic compositions | 温特穆特生物医学公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-112469409-A | Enantiomerically pure GPER agonists for the treatment of disease states and conditions | 林奈医疗股份有限公司 | 2021-03-09 | — | — | CN | disclosed |
| CN-107151245-B | A kind of preparation method of levo-praziquantel | 苏州同力生物医药有限公司 | 2019-04-05 | — | — | CN | disclosed |
| EP-2578561-A1 | Processes for the production of cannabidiol derivatives and intermediates thereof | Albany Molecular Research, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| EP-2578577-A1 | Sulfonyl esters of tetrahydrocannabinol and derivatives thereof | Albany Molecular Research, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| US-8106244-B2 | Process for production of delta-9-tetrahydrocannabinol | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20110263878-A1 | PROCESS FOR PRODUCTION OF DELTA-9-TETRAHYDROCANNABINOL | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20070093665-A1 | Process for production of delta-9- tetrahydrocannabinol | AMR TECHNOLOGY, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| WO-2007041167-A2 | PROCESS FOR PRODUCTION OF DELTA-9-TETRAHYDROCANNABINOL | AMR TECHNOLOGY, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-1994000986-A1 | PLANT GROWTH REGULATING COMPOSITIONS | CHURCH & DWIGHT COMPANY, INC. (US) | 1994-01-20 | — | — | WO | disclosed |
| EP-0281283-B1 | HETEROCYCLIC COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-02-10 | — | — | EP | disclosed |
| US-4910212-A | Containing 1,2,4-triazole or imidazole ring | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-03-20 | — | — | US | disclosed |
| EP-0281283-A1 | Heterocyclic compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-09-07 | — | — | EP | disclosed |
| US-4469516-A | Pigment preparations; process for their manufacture and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-09-04 | — | — | US | disclosed |
| US-4009085-A | ELECTRODEPOSITION OF CHROMIUM OXIDE | M & T CHEMICALS INC. (US) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093665-A1 | Process for production of delta-9- tetrahydrocannabinol | CNR2, CNR1, HRH4 | ALDH1A1 2849/4885CYP1A2 753/4885CYP2C9 28/4885 |
| US-20110263878-A1 | PROCESS FOR PRODUCTION OF DELTA-9-TETRAHYDROCANNABINOL | CNR2, CNR1, HRH4 | ALDH1A1 2849/4885CYP1A2 753/4885CYP2C9 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.